Article

Predict progression free survival and overall survival using objective response rate for anti - PD1 / PDL1 therapy development

2024-05-14

Abstract excerpt

<title>Abstract</title> <p>Background: In anti - PD1 (programmed death-1) / PDL1 (programmed death ligand 1) therapy development for solid tumors, the objective response rate (ORR) is a commonly used clinical endpoint for early phase study decision making, while progression free survival (PFS) and overall survival (OS) are widely used for late phase study decision making. Developing predictive models for median P...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d6d228f0-5a8b-573b-9ce6-09bc39ab130f
DOI: 10.21203/rs.3.rs-4379493/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Predict progression free survival and overall survival using objective response rate for anti - PD1 / PDL1 therapy developmentDOI 10.21203/rs.3.rs-4379493/v1Read

Robust prediction of patient outcomes with immune checkpoint blockade therapy for cancer using common clinical, pathologic, and genomic featuresSemantic proximity Read

SCOPE: Integrating Organoid Screening and Clinical Variables Through Machine Learning for Cancer Trial Outcome PredictionSemantic proximity Read

Predicting Success of Phase III Trials in OncologySemantic proximity Read

Predicting Individual Responses in Phase I Oncology Trials Using Routinely Collected Clinical BiomarkersSemantic proximity Read

Robust prediction of patient outcomes with immune checkpoint blockade therapy for cancer using common clinical, pathologic, and genomic featuresSemantic proximity Read

Machine learning model to predict oncologic outcomes for drugs in randomized clinical trials.Semantic proximity Read

Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptomeSemantic proximity Read

Survival Prediction Landscape: An In-Depth Systematic Literature Review on Activities, Methods, Tools, Diseases, and DatabasesSemantic proximity Read

Efficacy and Safety of Post-CDK4/6 Inhibitor Treatment Options for HR-Positive, HER2-Negative Advanced Breast Cancer: A Network Meta-Analysis of Randomized Controlled TrialsSemantic proximity Read

Multimodal profiling for prediction of primary resistance to anti–PD-(L)1 therapy in advanced non-small-cell lung cancer: the prospective PIONeeR biomarkers studySemantic proximity Read

Prediction of response to promising first-line chemotherapy in ovarian cancer patients with residual peritoneal tumors: Practical biomarkers and robust multiplex modelsSemantic proximity Read

Combining VEGFR tyrosine kinase inhibitors and PD-1/PD-L1 inhibitors versus VEGFR tyrosine kinase inhibitors monotherapy in renal cell carcinoma: a target trial emulationSemantic proximity Read